Cargando…
Circulating immune checkpoints predict heart failure outcomes
AIMS: There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). METHODS AND RESULTS: Transcriptomic analyses...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375122/ https://www.ncbi.nlm.nih.gov/pubmed/37186066 http://dx.doi.org/10.1002/ehf2.14304 |
_version_ | 1785078965030879232 |
---|---|
author | Screever, Elles M. Yousif, Laura I.E. Moslehi, Javid J. Salem, Joe‐Elie Voors, Adriaan A. Silljé, Herman H.W. de Boer, Rudolf A. Meijers, Wouter C. |
author_facet | Screever, Elles M. Yousif, Laura I.E. Moslehi, Javid J. Salem, Joe‐Elie Voors, Adriaan A. Silljé, Herman H.W. de Boer, Rudolf A. Meijers, Wouter C. |
author_sort | Screever, Elles M. |
collection | PubMed |
description | AIMS: There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). METHODS AND RESULTS: Transcriptomic analyses of cardiac tissue of three different HF mouse models revealed differentially expressed IC receptors and their ligands compared with control mice. Based on this observation, serum levels of three well‐known IC ligands (i.e. sPD‐L1, sPD‐L2 and galectin‐9) were measured in stable HF patients from the Vitamin D Chronic Heart Failure (VitD‐CHF) study (n = 101), as well as healthy individuals from the Prevention of Renal and Vascular End‐stage Disease (PREVEND) study (n = 58). sPD‐L1, sPD‐L2, and galectin‐9 were all associated with New York Heart Association classification. In multivariate linear regression analyses, all three IC ligands were associated with galectin‐3 (β = 0.230, β = 0.283, and β = 0.304, respectively). sPD‐L1 and galectin‐9 were also associated with hs‐troponin‐T (β = 0.386 and β = 0.314). Regarding prognosis, higher serum levels of sPD‐L1 and galectin‐9 were significantly associated with increased risk for HF hospitalization and all‐cause mortality [hazard ratio 1.69 (1.09–2.59) and hazard ratio 1.50 (1.06–2.12)]. Furthermore, the importance of IC ligands was tested in another stage of HF, namely worsening HF patients. In the worsening HF cohort (The BIOlogy Study to Tailored Treatment in Chronic Heart Failure) (n = 2032), sPD‐L2 and galectin‐9 were associated with New York Heart Association classification and significantly predicted outcome with an increased relative risk of 15% and 20%, after multivariable adjustment, respectively. CONCLUSIONS: IC ligands are expressed in cardiac disease models, and serum levels of IC ligands are elevated in HF patients, are associated with disease severity, and significantly predict prognosis. These data indicate a potential role for IC ligands in HF pathogenesis. |
format | Online Article Text |
id | pubmed-10375122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103751222023-07-29 Circulating immune checkpoints predict heart failure outcomes Screever, Elles M. Yousif, Laura I.E. Moslehi, Javid J. Salem, Joe‐Elie Voors, Adriaan A. Silljé, Herman H.W. de Boer, Rudolf A. Meijers, Wouter C. ESC Heart Fail Original Articles AIMS: There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). METHODS AND RESULTS: Transcriptomic analyses of cardiac tissue of three different HF mouse models revealed differentially expressed IC receptors and their ligands compared with control mice. Based on this observation, serum levels of three well‐known IC ligands (i.e. sPD‐L1, sPD‐L2 and galectin‐9) were measured in stable HF patients from the Vitamin D Chronic Heart Failure (VitD‐CHF) study (n = 101), as well as healthy individuals from the Prevention of Renal and Vascular End‐stage Disease (PREVEND) study (n = 58). sPD‐L1, sPD‐L2, and galectin‐9 were all associated with New York Heart Association classification. In multivariate linear regression analyses, all three IC ligands were associated with galectin‐3 (β = 0.230, β = 0.283, and β = 0.304, respectively). sPD‐L1 and galectin‐9 were also associated with hs‐troponin‐T (β = 0.386 and β = 0.314). Regarding prognosis, higher serum levels of sPD‐L1 and galectin‐9 were significantly associated with increased risk for HF hospitalization and all‐cause mortality [hazard ratio 1.69 (1.09–2.59) and hazard ratio 1.50 (1.06–2.12)]. Furthermore, the importance of IC ligands was tested in another stage of HF, namely worsening HF patients. In the worsening HF cohort (The BIOlogy Study to Tailored Treatment in Chronic Heart Failure) (n = 2032), sPD‐L2 and galectin‐9 were associated with New York Heart Association classification and significantly predicted outcome with an increased relative risk of 15% and 20%, after multivariable adjustment, respectively. CONCLUSIONS: IC ligands are expressed in cardiac disease models, and serum levels of IC ligands are elevated in HF patients, are associated with disease severity, and significantly predict prognosis. These data indicate a potential role for IC ligands in HF pathogenesis. John Wiley and Sons Inc. 2023-04-25 /pmc/articles/PMC10375122/ /pubmed/37186066 http://dx.doi.org/10.1002/ehf2.14304 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Screever, Elles M. Yousif, Laura I.E. Moslehi, Javid J. Salem, Joe‐Elie Voors, Adriaan A. Silljé, Herman H.W. de Boer, Rudolf A. Meijers, Wouter C. Circulating immune checkpoints predict heart failure outcomes |
title | Circulating immune checkpoints predict heart failure outcomes |
title_full | Circulating immune checkpoints predict heart failure outcomes |
title_fullStr | Circulating immune checkpoints predict heart failure outcomes |
title_full_unstemmed | Circulating immune checkpoints predict heart failure outcomes |
title_short | Circulating immune checkpoints predict heart failure outcomes |
title_sort | circulating immune checkpoints predict heart failure outcomes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375122/ https://www.ncbi.nlm.nih.gov/pubmed/37186066 http://dx.doi.org/10.1002/ehf2.14304 |
work_keys_str_mv | AT screeverellesm circulatingimmunecheckpointspredictheartfailureoutcomes AT yousiflauraie circulatingimmunecheckpointspredictheartfailureoutcomes AT moslehijavidj circulatingimmunecheckpointspredictheartfailureoutcomes AT salemjoeelie circulatingimmunecheckpointspredictheartfailureoutcomes AT voorsadriaana circulatingimmunecheckpointspredictheartfailureoutcomes AT silljehermanhw circulatingimmunecheckpointspredictheartfailureoutcomes AT deboerrudolfa circulatingimmunecheckpointspredictheartfailureoutcomes AT meijerswouterc circulatingimmunecheckpointspredictheartfailureoutcomes |